Pulmonary arterial hypertension (PAH) is a fatal condition characterized by abnormal vascular remodeling from excessive proliferation of pulmonary arterial smooth muscle cells (PASMCs). Recent evidence has suggested that structural maintenance of chromosomes 4 (SMC4) is upregulated in pulmonary tissue from patients with PAH and may be a potential target for therapy, since it has been tied to modulating pathological cell proliferation.
Atrium Therapeutics Inc. has obtained IND clearance from the FDA for ATR-1072 for the treatment of protein kinase AMP-activated non-catalytic subunit γ2 (PRKAG2) syndrome.
Wuhan Createrna Science and Technology Co. Ltd. has reported new complement factor D (CFD) inhibitors potentially useful for the treatment of cardiovascular, immunological, eye, genitourinary, renal, respiratory, neurological disorders and hematological diseases.
The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, has announced the teams for the THRIVE (Treating Hereditary Rare diseases with In Vivo prEcision genetic medicines) program. With a commitment of up to $160 million over 5 years, THRIVE aims to accelerate solutions for rare genetic pediatric diseases across multiple technological approaches, clinical trial designs and deployment models.
Apolin Bio Ltd. and Shanghai Viva Dancheng Entrepreneurship Incubator Management Ltd. have detailed polycyclic compounds acting as apolipoprotein A (ApoA; LPA)/apolipoprotein B-100 (APOB) interaction inhibitors that are potentially useful for the treatment of cardiovascular disorders.
FAM3D is a protein mainly expressed in the gastrointestinal tract, but also detectable in vascular endothelial cells. It is known to worsen intestinal inflammation by recruiting neutrophils, but its role in atherosclerosis is not well understood.
Shanghai Zheye Biotechnology LLC has discovered new phenylpropionic acid derivatives acting as apolipoprotein A (ApoA; LPA)/apolipoprotein B-100 (APOB) interaction inhibitors potentially useful for the treatment of stroke, atherosclerosis, thrombosis, coronary heart disease and aortic valve stenosis.
Bayer AG has patented new potassium channel Kir3.4 (GIRK4; KCNJ5) and/or Kir3.1/3.4 (GIRK1/4; KCNJ3/5) blockers potentially useful for the treatment of heart failure, arrhythmia, primary hyperaldosteronism and hypertension.
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have identified new calcitonin receptor (CALCR; CT-R) and amylin receptor dual agonists potentially useful for the treatment of metabolic dysfunction-associated steatohepatitis (MASH; NASH), overweight, dyslipidemia, cognitive and cardiovascular disorders.
Merck KGaA has entered into a strategic research-stage collaboration with Saturnus Bio, a biotech founded by Versant Ventures, to establish a foundational portfolio in the field of rare genetic cardiomyopathies.
RSS
